Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Read more
Sandoz announces agreement to acquire CIMERLI business from Coherus, strengthening position in US market Read more
FDA Grants Full Approval for BALVERSA to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations Read more
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis Read more
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Read more
bridgebio pharma secures up to $1.25 billion of capital from blue owl and cpp investments to accelerate the development and launch of genetic medicines Read more
Halozyme Announces argenx Received Approval in Japan for VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE for Generalized Myasthenia Gravis Read more
European Commission approves Roche’s Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types Read more
FDA Approves Takeda’s HYQVIA as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Read more
Vertex Announces FDA Approval of CASGEVY (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Read more